Akhil Kapoor: Intensifying Chemo in advanced Gastric Cancer doesn’t improve survivals

Akhil Kapoor, Associate Professor and Medical Oncology at TMH Varanasi, shared a post on X about a recent paper titled “Docetaxel-oxaliplatin-capecitabine/5 fluorouracil (DOC/F) followed by docetaxel versus Oxaliplatin-Capecitabine/5 fluorouracil (CAPOX/mFOLFOX-7) in HER2 negative advanced gastric cancers” published on JNCI.

Authors: Vikas Ostwal, Anant Ramaswamy, Prabhat Bhargava, Biswajit Dubashi, Anuj Gupta, Akhil Kapoor, Sujay Srinivas, Omshree Shetty, Poonam Jadhav, et al.

“Our Multicenter study led by Vikas Ostwal and Anant Ramaswamy published in JNCI.

• Intensifying Chemo in advanced Gastric Cancer doesn’t improve survivals
• Increases toxicities
• More is NOT always better.

Genomic Profiling revealed:

• Low incidence of microsatellite instability (1%)
• High incidence of BRCA1 (7.5%) and BRCA2 (8.4%) somatic alterations. Implications??”

Source: Akhil Kapoor/X